p53 in health and disease (original) (raw)

• Royds, J. A. & Iacopetta, B. p53 and disease: when the guardian angel fails. Cell Death Differ. 13, 1017–1026 (2006).
  CAS PubMed Google Scholar
• Vogelstein, B., Lane, D. & Levine, A. J. Surfing the p53 network. Nature 408, 307–310 (2000).
  CAS PubMed Google Scholar
• Donehower, L. A. The p53-deficient mouse: a model for basic and applied cancer studies. Sem. Cancer Biol. 7, 269–278 (1996).
  CAS Google Scholar
• Pietsch, E. C., Humbey, O. & Murphey, M. E. Polymorphisms in the p53 pathway. Oncogene 25, 1602–1611 (2006).
  CAS PubMed Google Scholar
• Lapenko, O. & Prives, C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 13, 951–961 (2006).
  Google Scholar
• Cawley, S. et al. Unbiased mapping of transcription factor binding sites along human chromosomes 21 and 22 points to widespread regulation of noncoding RNAs. Cell 116, 499–509 (2004).
  CAS PubMed Google Scholar
• Wei, C. -L. et al. A global map of p53 transcription-factor binding sites in the human genome. Cell 124, 207–219 (2006).
  CAS PubMed Google Scholar
• Matoba, S. et al. p53 regulates mitochondrial respiration. Science 312, 1650–1653 (2006). This paper provides evidence that loss of p53 might contribute to the Warburg effect.
  CAS PubMed Google Scholar
• Bensaad, K. et al. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126, 107–120 (2006).
  CAS PubMed Google Scholar
• Crighton, D. et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell 14, 121–134 (2006).
  Google Scholar
• Gatz, S. A. & Wiesmuller, L. p53 in recombination and repair. Cell Death Differ. 13, 1003–1016 (2006).
  CAS PubMed Google Scholar
• Bensaad, K. & Vousden, K. H. Savior and slayer: the two faces of p53. Nature Med. 11, 1278–1279 (2005).
  CAS PubMed Google Scholar
• Roger, L., Gadea, G. & Roux, P. Control of cell migration: a tumour suppressor function for p53? Biol. Cell 98, 141–152 (2006).
  CAS PubMed Google Scholar
• Kortleverm, R. M., Higgins, P. J. & Bernards, R. Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nature Cell Biol. 8, 877–884 (2006).
  Google Scholar
• Toeodoro, J. G., Parker, A. E., Zhu, X. & Green, M. R. p53-mediated inhibtion of angiogenesis through up-regulation of a collagen prolyl hydroxylase. Science 313, 968–971 (2006).
  Google Scholar
• Murray-Zmijewski, F., Lane, D. P. & Bourdon, J. C. p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 13, 962–972 (2006).
  CAS PubMed Google Scholar
• Wang, X. et al. p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling. J. Cell Biol. 172, 115–125 (2006).
  CAS PubMed PubMed Central Google Scholar
• Yee, K. S. & Vousden, K. H. Complicating the complexity of p53. Carcinogenesis 26, 1317–1322 (2005).
  CAS PubMed Google Scholar
• Moll, U. M., Wolff, S., Speidel, D. & Deppert, W. Transcription-independent pro-apoptotic functions of p53. Curr. Opin. Cell Biol. 17, 631–636 (2005).
  CAS PubMed Google Scholar
• Yu, J. & Zhang, L. No PUMA, no death: implications for p53-dependent apoptosis. Cancer Cell 4, 248–249 (2003).
  CAS PubMed Google Scholar
• Strom, E. et al. Small-molecule inhibitor of p53 binding to mitochondria protects mice from γ radiation. Nature Chem. Biol. 2, 474–479 (2006).
  CAS Google Scholar
• Chipuk, J. E., Bouchier-Hayes, L., Kuwana, T., Newmeyer, D. D. & Green, D. R. PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science 309, 1732–1735 (2005). An elegant study that consolidates the transcriptionally dependent and independent activities of p53 into a single model.
  CAS PubMed Google Scholar
• Levine, A. J., Hu, W. & Feng, Z. The p53 pathway: what questions remain to be explored? Cell Death Differ. 13, 1027–1036 (2006).
  CAS PubMed Google Scholar
• Brooks, C. L. & Gu, W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 21, 307–315 (2006).
  CAS PubMed PubMed Central Google Scholar
• Braithwaite, A. W., Del Sal, G. & Lu, X. Some p53-binding proteins that can function as arbiters of life and death. Cell Death Differ. 13, 984–993 (2006).
  CAS PubMed Google Scholar
• Harris, S. L. & Levine, A. J. The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899–2908 (2005).
  CAS PubMed Google Scholar
• Marine, J. C. et al. Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ. 13, 927–934 (2006).
  CAS PubMed Google Scholar
• Nordstrom, W. & Abrams, J. M. Guardian ancestry: fly p53 and damage-inducible apoptosis. Cell Death Differ. 7, 1035–1038 (2000).
  CAS PubMed Google Scholar
• Derry, W. B., Putzke, A. P. & Rothman, J. H. Caenorhabditis elegans p53: role in apoptosis, meiosis and stress resistance. Science 294, 591–595 (2001).
  CAS PubMed Google Scholar
• Schumacher, B., Hofmann, K., Boulton, S. & Gartner, A. The C. elegans homolog of the p53 tumor suppressor is required for DNA damage-induced apoptosis. Curr. Biol. 11, 1722–1727 (2001).
  CAS PubMed Google Scholar
• Kamijo, T. et al. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function. Cancer Res. 59, 2464–2469 (1999).
  CAS PubMed Google Scholar
• Lohrum, M. A., Ludwig, R. L., Kubbutat, M. H. G., Hanlon, M. & Vousden, K. H. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3, 577–587 (2003).
  CAS PubMed Google Scholar
• Christophorou, M. A., Ringhausen, I., Finch, A. J., Brown Swigart, L. & Evan, G. I. The pathological p53-mediated response to DNA damage is distinct from p53-mediated tumor suppression. Nature 14, 214–217 (2006).
  Google Scholar
• Efeyan, A., Garcia-Cao, I., Herranz, D., Velasco-Miguel, S. & Serrano, M. Policing of oncogene activity by p53. Nature 443, 159 (2006). References 33 and 34 suggest that the response to oncogene activation, but not to DNA damage, is crucial for p53-mediated tumour suppression.
  CAS PubMed Google Scholar
• Bartkova, J. et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigensis. Nature 434, 864–870 (2005).
  CAS PubMed Google Scholar
• Gorgoulis, V. G. et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 434, 907–913 (2005). Two studies that, in contrast to 33 and 34, show the importance of the DNA-damage signal to tumour suppression.
  CAS PubMed Google Scholar
• Lassus, P., Ferlin, M., Piette, J. & Hibner, U. Anti-apoptotic activity of low levels of wild type p53. EMBO J. 15, 4566–4573 (1996).
  CAS PubMed PubMed Central Google Scholar
• Jones, R. G. et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283–293 (2005).
  CAS PubMed Google Scholar
• Stambolsky, P. et al. Regulation of AIF expression by p53. Cell Death Differ. 13, 2140–2149 (2006).
  CAS PubMed Google Scholar
• Johnson, T. M., Yu, Z.-X., Ferrans, V. J., Lowenstein, R. A. & Finkel, T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc. Natl Acad. Sci. USA 93, 11848–11852 (1996).
  CAS PubMed PubMed Central Google Scholar
• Polyak, K., Xia, Y., Zweier, J. L., Kinzler, K. W. & Vogelstein, B. A model for p53-induced apoptosis. Nature 389, 300–305 (1997).
  CAS PubMed Google Scholar
• Velasco-Miguel, S. et al. PA26, a novel target of the p53 tumor suppressor and member of the GADD family of DNA damage and growth arrest inducible genes. Oncogene 18, 127–137 (1999).
  CAS PubMed Google Scholar
• Budanov, A. V., Sablina, A. A., Feinstein, E., Koonin, E. V. & Chumakov, P. M. Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 304, 596–600 (2004).
  CAS PubMed Google Scholar
• Yoon, K. A., Nakamura, Y. & Arakawa, H. Identification of ALDH4 as a p53-inducible gene and its protective role in cellular stresses. J. Hum. Genet. 49, 134–140 (2004).
  CAS PubMed Google Scholar
• Gu, S. et al. Global investigation of p53-induced apoptosis through quantitative proteomic profiling using comparative amino acid-coded tagging. Mol. Cell. Proteomics 3, 998–1008 (2006).
  Google Scholar
• Sablina, A. A. et al. The antioxidant function of the p53 tumor suppressor gene. Nature Med. 11, 1306–1313 (2005). A demonstration of the antioxidant activity of basal levels of p53.
  CAS PubMed Google Scholar
• Hemann, M. T. et al. Suppression of tumorigenesis by the p53 target PUMA. Proc. Natl Acad. Sci. USA 101, 9333–9338 (2004).
  CAS PubMed PubMed Central Google Scholar
• Lowe, S. W., Cepero, E. & Evan, G. Intrinsic tumour suppression. Nature 432, 307–315 (2004).
  CAS PubMed Google Scholar
• Liu, G. et al. Chromosomal stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nature Genet. 36, 63–68 (2004).
  CAS PubMed Google Scholar
• Dimri, G. P. What has senescence got to do with cancer? Cancer Cell 7, 505–512 (2005).
  CAS PubMed PubMed Central Google Scholar
• Barbieri, C. E. & Pietenpol, J. A. p63 and epithelial biology. Exp. Cell Res. 312, 695–706 (2006).
  CAS PubMed Google Scholar
• Flores, E. R. et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7, 363–373 (2005).
  CAS PubMed Google Scholar
• Sutcliffe, J. E. & Brehm, A. Of flies and men; p53, a tumour suppressor. FEBS Lett. 567, 86–91 (2004).
  CAS PubMed Google Scholar
• Mills, A. A. p53: link to the past, bridge to the future. Genes Dev. 19, 2091–2099 (2005).
  CAS PubMed Google Scholar
• Chio, J. & Donehower, L. A. p53 in embryonic development: maintaining a fine balance. CMLS Cell. Mol. Life Sci. 55, 38–47 (1999).
  Google Scholar
• Armstrong, J. F., Kaufman, M. H., Harrison, D. J. & Clarke, A. R. High-frequency developmental abnormalities in p53-deficient mice. Curr. Biol. 5, 931–936 (1995).
  CAS PubMed Google Scholar
• Sah, V. P. et al. A subset of p53-deficient embyos exhibit exencephaly. Nature Genet. 10, 175–180 (1995).
  CAS PubMed Google Scholar
• Hall, P. A. & Lane, D. P. Tumor suppressors: a developing role for p53? Curr. Biol. 7, R144–R147 (1997).
  CAS PubMed Google Scholar
• Baatout, S. et al. Developmental abnormalities induced by X-irradiation in p53 deficient mice. In Vivo. 16, 215–221 (2002).
  CAS PubMed Google Scholar
• Azuma, M., Toyama, R., Laver, E. & Dawid, I. B. Perturbation of rRNA synthesis in the bap28 mutation leads to apoptosis mediated by p53 in the zebrafish central nervous system. J. Biol. Chem. 281, 13309–13316 (2006).
  CAS PubMed Google Scholar
• Plaster, N., Sonntag, C., Busse, C. E. & Hammerschmidt, M. p53 deficiency rescues apoptosis and differentiation of multiple cell types in zebrafish flathead mutants deficient for zygotic DNA polymerase δ1. Cell Death Differ. 13, 223–235 (2006).
  CAS PubMed Google Scholar
• Chen, J. et al. Loss of function of def selectively up-regulates Δ113p53 expression to arrest expansion growth of digestive organs in zebrafish. Genes Dev. 19, 2900–2911 (2005).
  CAS PubMed PubMed Central Google Scholar
• Campbell, W. A. et al. Zebrafish lacking Alzheimer presenilin enhancer 2 (Pen-2) demonstrate excessive p53-dependent apoptosis and neuronal loss. J. Neurochem. 96, 1423–1440 (2006).
  CAS PubMed Google Scholar
• Nicol, C. J., Harrison, M. L., Laposa, R. R., Gimelshtein, I. L. & Well, P. G. A teratologic suppressor role for p53 in benzo(a)pyrene-treated transgenic p53-deficient mice. Nature Genet. 10, 181–187 (1995).
  CAS PubMed Google Scholar
• Norimura, T., Nomoto, S., Katsuki, M., Gondo, Y. & Kondo, S. _p53_-dependent apoptosis suppresses radiation-induced teratogenesis. Nature Med. 2, 577–580 (1996).
  CAS PubMed Google Scholar
• Varley, J. M. Germline TP53 mutations and Li–Fraumeni syndrome. Hum. Mutat. 21, 313–320 (2003).
  CAS PubMed Google Scholar
• Georgiev, P., Dahm, F., Graf, R. & Clavien, P. A. Blocking the path to death: anti-apoptotic molecules in ischemia/reperfusion injury of the liver. Curr. Pharm. Des. 12, 2911–2921 (2006).
  CAS PubMed Google Scholar
• Fiskum, G. et al. Protection against ischemic brain injury by inhibition of mitochondrial oxidative stress. J. Bioenerg. Biomembr. 36, 347–352 (2004).
  CAS PubMed Google Scholar
• Dagher, P. C. Apoptosis in ischemic renal injury: roles of GTP depletion and p53. Kidney Int. 66, 506–509 (2004).
  CAS PubMed Google Scholar
• Matsusaka, H. et al. Targeted deletion of p53 prevents cardiac rupture after myocardial infarction in mice. Cardiovasc. Res. 70, 457–465 (2006).
  CAS PubMed Google Scholar
• Jacobs, W. B., Kaplan, D. R. & Miller, F. D. The p53 family in nervous system development and disease. J. Neurochem. 97, 1571–1584 (2006).
  CAS PubMed Google Scholar
• Tyner, S. D. et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 415, 45–53 (2002).
  CAS PubMed Google Scholar
• Maier, B. et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev. 18, 306–319 (2004).
  CAS PubMed PubMed Central Google Scholar
• van Heemst, D. et al. Variation in the human TP53 gene affects old age survival and cancer mortality. Exp. Gerontol. 40, 11–15 (2005).
  CAS PubMed Google Scholar
• Sharpless, N. E. & DePinho, R. A. Telomeres, stem cells, senescence, and cancer. J. Clin. Invest. 113, 160–168 (2004).
  CAS PubMed PubMed Central Google Scholar
• Bauer, J. H., Poon, P. C., Glatt-Deeley, H., Abrams, J. M. & Helfand, S. L. Neuronal expression of p53 dominant-negative proteins in adult Drosophila melanogaster extends life span. Curr. Biol. 15, 2063–2068 (2005).
  CAS PubMed Google Scholar
• Bauer, J. H. & Helfand, S. L. New tricks of an old molecule: lifespan regulation by p53. Aging Cell 5, 437–440 (2006).
  CAS PubMed Google Scholar
• Bourdon, J. C. et al. p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19, 2122–2137 (2005).
  CAS PubMed PubMed Central Google Scholar
• Kondoh, H. et al. Glycolytic enzymes can modulate cellular lifespan. Cancer Res. 65, 177–185 (2005).
  CAS PubMed Google Scholar
• Garcia-Cao, I. et al. “Super p53” mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21, 6225–6235 (2002).
  CAS PubMed PubMed Central Google Scholar
• Mendrysa, S. M. et al. Tumor suppression and normal aging in mice with constitutively high p53 activity. Genes Dev. 20, 16–21 (2006). References 80 and 81 show that increasing the copy number of p53 while maintaining normal control over expression does not result in enhanced ageing.
  CAS PubMed PubMed Central Google Scholar
• Mendrysa, S. M. & Perry, M. E. Tumor suppression by p53 without acceletated aging: just enough of a good thing? Cell Cycle 5, 714–717 (2006).
  CAS PubMed Google Scholar
• Poyurovsky, M. V. & Prives, C. Unleashing the power of p53: lessons from mice and men. Genes Dev. 20, 125–131 (2006).
  CAS PubMed Google Scholar
• Wells, B. S., Yoshida, E. & Johnston, L. A. Compensatory proliferation in Drosophila imaginal discs requires Dronc-dependent p53 activity. Curr. Biol. 16, 1606–1615 (2006).
  CAS PubMed PubMed Central Google Scholar
• Vousden, K. H. & Lu, X. Live or let die: the cell's response to p53. Nature Rev. Cancer 2, 594–604 (2002).
  CAS Google Scholar
• Christophorou, M. A. et al. Temporal diffection of p53 function in vitro and in vivo. Nature Genet. 37, 718–726 (2005).
  CAS PubMed Google Scholar
• Soussi, T. & Lozano, G. p53 mutation heterogeneity in cancer. Biochem. Biophys. Res. Com. 331, 834–842 (2005).
  CAS PubMed Google Scholar
• Lang, G. A. et al. Gain-of-function of a p53 hot spot mutation in a mouse model of Li–Fraumeni syndrome. Cell 119, 861–872 (2004).
  CAS PubMed Google Scholar
• Olive, K. P. et al. Mutant p53 gain-of-function in two mouse models of Li–Fraumeni syndrome. Cell 119, 847–860 (2004). Two sophisticated studies showing the effects of expression of mutant p53 in mouse models.
  CAS PubMed Google Scholar
• Irwin, M. S. Family feud in chemosensitivity: p73 and mutant p53. Cell Cycle 3, 319–323 (2004).
  CAS PubMed Google Scholar
• Sigal, A. & Rotter, V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res. 60, 6788–6793 (2000).
  CAS PubMed Google Scholar
• Kim, E. & Deppert, W. Transcriptional activities of mutant p53: when mutations are more than a loss. J. Cell Biochem. 93, 878–886 (2004).
  CAS PubMed Google Scholar
• Bond, G. L. et al. A single nucleotide polymorphism in the Mdm2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119, 591–602 (2004).
  CAS PubMed Google Scholar
• Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecular antagonists of MDM2. Science 303, 844–848 (2004). One of a number of studies describing small-molecule activators of p53.
  CAS PubMed Google Scholar
• Issaeva, N. et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nature Med. 10, 1321–1328 (2004).
  CAS PubMed Google Scholar
• Yang, Y. et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7, 547–559 (2005).
  CAS PubMed Google Scholar
• Komarov, P. G. et al. A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science 285, 1733–1737 (1999). The description of a small-molecule inhibitor of p53
  CAS PubMed Google Scholar
• Green, D. R. Apoptotic pathways: the roads to ruin. Cell 94, 695–698 (1998).
  CAS PubMed Google Scholar
• Danial, N. N. & Korsmeyer, S. J. Cell death: critical control points. Cell 116, 205–219 (2004).
  CAS PubMed Google Scholar
• Cory, S. & Adams, J. M. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Rev. Cancer 2, 647–656 (2002).
  CAS Google Scholar
• Jeffers, J. R. et al. Puma is an essential mediator of p53-dependent and-independent apoptotic pathways. Cancer Cell 4, 321–328 (2003).
  CAS PubMed Google Scholar
• Villunger, A. et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins Puma and Noxa. Science 302, 1036–1038 (2003).
  CAS PubMed Google Scholar
• Vousden, K. H. p53 and PUMA: a deadly duo. Science 309, 1685–1686 (2005).
  CAS PubMed Google Scholar
• Parks, D. J. et al. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2–p53 protein–protein interaction through structure-based drug design. Bioog. Med. Chem. Lett. 16, 3310–3314 (2006).
  CAS Google Scholar
• Ding, K. et al. Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc. 127, 10130–10131 (2005).
  CAS PubMed Google Scholar
• Lai, Z. et al. Differentiation of Hdm2-mediated p53 ubiquitination and Hdm2 autoubiquitination activity by small molecular weight inhibitors. Proc. Natl Acad. Sci. USA 99, 14734–14739 (2002).
  CAS PubMed PubMed Central Google Scholar
• Foster, B. A., Coffey, H. A., Morin, M. J. & Rastinejad, F. Pharmacological rescue of mutant p53 conformation and function. Science 286, 2507–2510 (1999).
  CAS PubMed Google Scholar
• Bykov, V. J. N. et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nature Med. 8, 282–288 (2002).
  CAS PubMed Google Scholar
• Gudkov, A. V. & Komarova, E. A. Prospective therapeutic applications of p53 inhibitors. Biochem. Biophys. Res. Com. 331, 726–736 (2005).
  CAS PubMed Google Scholar